Author:
Li Zhan-Guo,He Jing,Miao Miao
Reference17 articles.
1. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial;Hartemann;Lancet Diabetes Endocrinol,2013
2. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus;He;Nat Med,2016
3. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial;He;Ann Rheum Dis,2020
4. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial;Humrich;Ann Rheum Dis,2022
5. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial;Humrich;Lancet Rheumatol,2019